https://molibresibinhibitor.co....m/does-strategy-for-
Therefore, we investigated the employment of such variables in FDG-PET/CT exams ahead of the start of immunotherapy with vemurafenib or ipilimumab in patients with cancerous melanoma. TECHNIQUES In this retrospective analysis 26 clients with histologically proven advanced melanoma had been included. FGD-PET/CT was performed prior to the start of treatment either with vemurafenib (n = 9) or ipilimumab (n = 17) and tumors were examined for textural variables in addition to mainstr
Like
Comment
Share
